Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
SHC 
Sotera Health Co (SHC)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/27/2025: SHC (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
8 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $17
1 Year Target Price $17
| 3 | Strong Buy |
| 2 | Buy |
| 3 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -8.35% | Avg. Invested days 39 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/27/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 4.79B USD | Price to earnings Ratio 187.33 | 1Y Target Price 17 |
Price to earnings Ratio 187.33 | 1Y Target Price 17 | ||
Volume (30-day avg) 8 | Beta 1.82 | 52 Weeks Range 9.53 - 17.15 | Updated Date 10/27/2025 |
52 Weeks Range 9.53 - 17.15 | Updated Date 10/27/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.09 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 2.14% | Operating Margin (TTM) 35.34% |
Management Effectiveness
Return on Assets (TTM) 7.24% | Return on Equity (TTM) 5.14% |
Valuation
Trailing PE 187.33 | Forward PE 20.2 | Enterprise Value 6527937103 | Price to Sales(TTM) 4.26 |
Enterprise Value 6527937103 | Price to Sales(TTM) 4.26 | ||
Enterprise Value to Revenue 5.8 | Enterprise Value to EBITDA 15.73 | Shares Outstanding 284046606 | Shares Floating 139276572 |
Shares Outstanding 284046606 | Shares Floating 139276572 | ||
Percent Insiders 2.46 | Percent Institutions 90.65 |
Upturn AI SWOT
Sotera Health Co
Company Overview
History and Background
Sotera Health Co. was formed in 2017 through the combination of Sterigenics, Nordion, and Nelson Labs. These companies each have a long history, with some tracing back to the early 20th century. The company focuses on providing sterilization, lab testing, and advisory services to the healthcare industry.
Core Business Areas
- Sterilization Services: Provides gamma, electron beam, and X-ray irradiation, as well as ethylene oxide processing, for medical devices and pharmaceuticals. This segment is critical for ensuring product safety and efficacy.
- Lab Testing Services: Offers microbiological and analytical testing services to ensure product safety and regulatory compliance. Nelson Labs is a key component of this segment.
- Advisory Services: Provides consulting services to assist clients with sterilization validation, regulatory compliance, and product development.
Leadership and Structure
Sotera Health is led by a board of directors and a management team. Key executives include the CEO, CFO, and heads of the various business segments. The company has a global presence and operates through multiple facilities worldwide.
Top Products and Market Share
Key Offerings
- Gamma Sterilization: A widely used sterilization method for medical devices. Sotera Health holds a significant market share in this area. Competitors include Steris (STE) and other smaller sterilization providers. Hard to calculate market share, but believed to be around 20%.
- Ethylene Oxide (EtO) Sterilization: Effective for sterilizing heat-sensitive devices. This area has faced increased scrutiny due to environmental concerns. Sotera Health's share in this is estimated to be around 25%. Competitors are Steris(STE) and WuXi AppTec (WXTSF)
- Lab Testing Services (Nelson Labs): Offers a range of microbiological and analytical testing services for medical devices and pharmaceuticals. The lab testing services hold about 20-25% market share with many smaller providers such as Eurofins Scientific (ERFSF) and Charles River Laboratories (CRL) as competitors.
Market Dynamics
Industry Overview
The healthcare sterilization and testing market is growing due to increasing demand for medical devices, stricter regulatory requirements, and growing awareness of infection control. Consolidation is ongoing within the industry.
Positioning
Sotera Health is a leading provider of sterilization and lab testing services. Its competitive advantages include its scale, global reach, comprehensive service offerings, and established relationships with medical device manufacturers.
Total Addressable Market (TAM)
The global sterilization services market is expected to reach approximately $10 billion USD by 2027. Sotera Health is well-positioned to capture a significant share of this TAM due to its established market presence and comprehensive service offerings.
Upturn SWOT Analysis
Strengths
- Leading market position
- Comprehensive service offerings
- Global network of facilities
- Strong customer relationships
- Established regulatory expertise
Weaknesses
- Ethylene Oxide (EtO) risks and associated potential liabilities
- Reliance on the medical device industry
- Potential for increased regulatory scrutiny
- Exposure to environmental regulations and compliance costs
Opportunities
- Expanding into emerging markets
- Developing new sterilization technologies
- Acquiring smaller competitors
- Increasing demand for outsourced testing services
- Offering value added consulting services
Threats
- Increased competition
- Stricter environmental regulations (EtO)
- Product liability lawsuits
- Technological obsolescence
- Economic downturns impacting healthcare spending
Competitors and Market Share
Key Competitors
- STE
- CRL
- WXTSF
Competitive Landscape
Sotera Health's advantages include its scale and comprehensive service offerings. Disadvantages include risks associated with EtO sterilization and litigation.
Major Acquisitions
Nelson Labs
- Year: 2014
- Acquisition Price (USD millions): 675
- Strategic Rationale: Expanded Sotera Health's lab testing capabilities and strengthened its position in the healthcare market.
Growth Trajectory and Initiatives
Historical Growth: Sotera Health's growth has been driven by organic expansion and acquisitions. Consult SEC filings for historical growth.
Future Projections: Analyst estimates vary, but the consensus is for continued growth in the sterilization and lab testing markets. Analyst projections should be verified directly to avoid stale data.
Recent Initiatives: Recent initiatives could include expansion of service offerings, acquisitions, and investments in new technologies. This should be verified directly from company announcements.
Summary
Sotera Health is a leading provider of sterilization and lab testing services, benefiting from a growing market and comprehensive service offerings. Its EtO-related risks present a challenge, but its strategic acquisitions and market position support continued growth. The company must navigate increasing regulatory scrutiny and competition to maintain its strong performance. Recent positive court verdicts regarding EtO liabilities have bolstered investor confidence, but continuous monitoring is vital.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Sotera Health Investor Relations
- SEC Filings
- Market Research Reports
- Analyst Reports
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Market data and analyst estimates are subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Sotera Health Co
Exchange NASDAQ | Headquaters Broadview Heights, OH, United States | ||
IPO Launch date 2020-11-20 | Chairman & CEO Mr. Michael B. Petras Jr. | ||
Sector Healthcare | Industry Diagnostics & Research | Full time employees 3000 | Website https://soterahealth.com |
Full time employees 3000 | Website https://soterahealth.com | ||
Sotera Health Company provides sterilization, lab testing, and advisory services for the healthcare industry in the United States, Canada, Europe, and internationally. The company operates through three segments: Sterigenics, Nordion, and Nelson Labs. The Sterigenics segment offers outsourced terminal sterilization and irradiation services using gamma irradiation, ethylene oxide processing, and electron beam irradiation technologies for the medical device, pharmaceutical, and food safety and advanced applications markets. The Nordion segment provides Cobalt-60 used in the sterilization and irradiation processes for the medical device, pharmaceutical, food safety, and high-performance materials industries, as well as in the treatment of cancer. It also offers gamma irradiation systems. The Nelson Labs segment provides outsourced microbiological and analytical chemistry testing and advisory services for the medical device and pharmaceutical industries. The company was formerly known as Sotera Health Topco, Inc. and changed its name to Sotera Health Company in October 2020. Sotera Health Company was incorporated in 2015 and is headquartered in Broadview Heights, Ohio.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.